COMPETING INTERESTS
V.R., C.R., M.P-B, L.H.V., and E.A are inventors on a patent describing
the Anc80 baculovirus expression vector. E.A. is a consultant for AAV
gene therapy companies. L.H.V. is an inventor on several patents related
to AAV gene therapy, including AncAAV variants, AAV9, and method
patents, which are licensed to several biopharma companies. L.H.V.
further receives funding from Lonza/Houston, Selecta Biosciences, and
Solid Biosci- ences, licensors to AncAAV technology. L.H.V. is a
consultant to Nightstar, Selecta, Akouos, and Exonics and a founder of
Akouos. L.H.V. has a financial interest in TDTx, a company developing
AAV gene therapies; he is an inventor of technology related to AAV gene
therapy, a founder of the company, and also serves on its Board of
Directors. L.H.V.’s interests were reviewed and are managed by MEE and
Partners HealthCare in accordance with their conflicts of interest
policies.